Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| B9R-FP-GDGI | Other Identifier | Eli Lilly and Company |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The present randomized trial was initially intended to study the benefits of a combined treatment with growth hormone (GH) and a gonadotropin-releasing hormone (GnRH) agonist for pubertal children with idiopathic short stature. However, treatments were stopped in January 2012 at the request of the French drug agency. Therefore, a protocol amendment divided the study in two study periods.
Study Period 1 involved combined treatment with somatropin and leuprorelin or treatment with somatropin alone. Participants from France who participated in this Period 1 of the study were asked to participate in a long term safety follow up defined as a Period 2 of the study. Participants from the Netherlands were offered participation in Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS, clinicaltrials.gov Identifier: NCT01088412) for long term safety follow up independent of this study.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental |
| |
| 2 | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| somatropin | Drug | 0.05 mg/kg/day |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With One or More Drug-related Adverse Events | A drug-related AE was an AE that occurred postdose or was present predose and became more severe postdose and was considered to be related to study treatment. A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section. | Baseline through End of Study (up to 9 years) |
| Adult Height Standard Deviation Score (SDS) | The height of the participants were measured barefoot using a standard wall-mounted Harpenden stadiometer. SDS report the number of standard deviations from the mean for age and sex for an individual measurement (normal range: -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height. | Baseline through End of Study (up to 9 years) |
| Measure | Description | Time Frame |
|---|---|---|
| Height Velocity | Height velocity is the difference between 2 height measurements, divided by years elapsed between measurements. | Baseline through End of Study (up to 9 years) |
| Height SDS | SDS report the number of standard deviations from the mean for age and sex for an individual measurement (normal range: -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) | Eli Lilly and Company | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Amiens | 80084 |
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement
Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Somatropin and Leuprorelin: Experimental Arm 1 | 0.05mg/kg/day subcutaneous somatropin and 3-month formulation, subcutaneous or intramuscular injection of 11.25mg leuprorelin for three years (or for a minimum of 2 years until a chronological age of 13 years for girls and 15 years for boys, whichever occurs first). |
| FG001 |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Study Period 1 Treatment |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| leuprorelin | Drug | 11.25 mg/3 months |
|
| Baseline through End of Study (up to 9 years) |
| Difference Between Adult Height SDS and Target Height SDS | This is the difference between the gender, age and country matched standard deviation score of adult height and standard deviation score of target height [calculated as (mother's height (SDS) + father's height (SDS))/2] for particular participant. The height of the participants were measured barefoot using a standard wall-mounted Harpenden stadiometer. SDS report the number of standard deviations from the mean for age and sex for an individual measurement (normal range: -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height. | Baseline through End of Study (up to 9 years) |
| Difference Between Adult Height SDS and Baseline Predicted Height SDS | This is the difference between the gender, age and country matched standard deviation score of adult height and standard deviation score of baseline predicted height [calculated using the Bayley-Pinneau method based on height and bone age] for particular participant. The height of the participants were measured barefoot using a standard wall-mounted Harpenden stadiometer. SDS report the number of standard deviations from the mean for age and sex for an individual measurement (normal range: -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height. | Baseline through End up Study (up to 9 years) |
| Difference Between Adult Height SDS and Baseline Height SDS | This is the difference between the gender, age and country matched standard deviation score of adult height and standard deviation score of baseline height for particular participant. The height of the participants were measured barefoot using a standard wall-mounted Harpenden stadiometer. SDS report the number of standard deviations from the mean for age and sex for an individual measurement (normal range: -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height. | Baseline through End up Study (up to 9 years) |
| Percentage of Children With Normal Adult Height SDS | Percentage of children with normal adult height SDS (greater than -2 SDS and less than +2 SDS) | Baseline through End of Study (up to 9 years) |
| Bone Age | Bone age measured using the X-Ray of left hand and wrist. | Baseline through End of Study (up to 9 years) |
| France |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Besançon | 25030 | France |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Bordeaux | 33076 | France |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Boulogne | 92100 | France |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Le Havre | 76083 | France |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Lille | 59037 | France |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Lyon | 69322 | France |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Marseille | 13385 | France |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Nice | 06200 | France |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Paris | 75743 | France |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Reims | 51092 | France |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Rennes | 35056 | France |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Rouen | 76036 | France |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Saint-Etienne | 42055 | France |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Strasbourg | 67 098 | France |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Tarbes | 65000 | France |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Toulouse | 31026 | France |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Nijmegen | 6525 GM | Netherlands |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Rotterdam | 3015 GD | Netherlands |
| Somatropin: Experimental Arm 2 |
0.05mg/kg/day subcutaneous somatropin only |
| Received At Least One Dose of Study Drug |
|
| COMPLETED |
|
| NOT COMPLETED |
|
|
| Study Period 2 Long Term Follow-Up |
|
|
The full analysis set (FAS) includes all data from all randomized patients receiving at least one dose of the study drug according to the treatment to which the patients were assigned and with at least one follow-up visit.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Somatropin and Leuprorelin | 0.05mg/kg/day subcutaneous somatropin and 3-month formulation, subcutaneous or intramuscular injection of 11.25mg leuprorelin for three years (or for a minimum of 2 years until a chronological age of 13 years for girls and 15 years for boys, whichever occurs first). |
| BG001 | Somatropin | 0.05mg/kg/day subcutaneous somatropin only |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Region of Enrollment | Number | participants |
| ||||||||||||||||
| Standing Height SDS | Mean | Standard Deviation | Standard Deviation Score |
| |||||||||||||||
| Standing Height | Mean | Standard Deviation | centimeters |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants With One or More Drug-related Adverse Events | A drug-related AE was an AE that occurred postdose or was present predose and became more severe postdose and was considered to be related to study treatment. A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section. | All participants who received at least one dose of study drug in Period 1 and all participants who entered Period 2 (safety population). | Posted | Number | participants | Baseline through End of Study (up to 9 years) |
|
|
| ||||||||||||||||||||||||||||||||||||
| Primary | Adult Height Standard Deviation Score (SDS) | The height of the participants were measured barefoot using a standard wall-mounted Harpenden stadiometer. SDS report the number of standard deviations from the mean for age and sex for an individual measurement (normal range: -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height. | All participants who received at least one dose of study drug with at least one follow up visit. | Posted | Mean | Standard Deviation | standard deviation score | Baseline through End of Study (up to 9 years) |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Height Velocity | Height velocity is the difference between 2 height measurements, divided by years elapsed between measurements. | All participants who received at least one dose of study drug with at least one follow up visit. The safety follow up participants did not reach final height at end of Period 1 unless final height is noted for participants that reached final height at the end of Period 1. | Posted | Mean | Standard Deviation | centimeter per year | Baseline through End of Study (up to 9 years) |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Height SDS | SDS report the number of standard deviations from the mean for age and sex for an individual measurement (normal range: -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height. | All participants who received at least one dose of study drug with at least one follow up visit. The safety follow up participants did not reach final height at end of Period 1 unless final height is noted for participants that reached final height at the end of Period 1. | Posted | Mean | Standard Deviation | standard deviation score | Baseline through End of Study (up to 9 years) |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Difference Between Adult Height SDS and Target Height SDS | This is the difference between the gender, age and country matched standard deviation score of adult height and standard deviation score of target height [calculated as (mother's height (SDS) + father's height (SDS))/2] for particular participant. The height of the participants were measured barefoot using a standard wall-mounted Harpenden stadiometer. SDS report the number of standard deviations from the mean for age and sex for an individual measurement (normal range: -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height. | All participants who received who reached final height. | Posted | Mean | Standard Deviation | standard deviation score | Baseline through End of Study (up to 9 years) |
| |||||||||||||||||||||||||||||||||||||
| Secondary | Difference Between Adult Height SDS and Baseline Predicted Height SDS | This is the difference between the gender, age and country matched standard deviation score of adult height and standard deviation score of baseline predicted height [calculated using the Bayley-Pinneau method based on height and bone age] for particular participant. The height of the participants were measured barefoot using a standard wall-mounted Harpenden stadiometer. SDS report the number of standard deviations from the mean for age and sex for an individual measurement (normal range: -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height. | All participants who received who reached final height. | Posted | Mean | Standard Deviation | standard deviation score | Baseline through End up Study (up to 9 years) |
| |||||||||||||||||||||||||||||||||||||
| Secondary | Difference Between Adult Height SDS and Baseline Height SDS | This is the difference between the gender, age and country matched standard deviation score of adult height and standard deviation score of baseline height for particular participant. The height of the participants were measured barefoot using a standard wall-mounted Harpenden stadiometer. SDS report the number of standard deviations from the mean for age and sex for an individual measurement (normal range: -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height. | All participants who received who reached final height. | Posted | Mean | Standard Deviation | standard deviation score | Baseline through End up Study (up to 9 years) |
| |||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Children With Normal Adult Height SDS | Percentage of children with normal adult height SDS (greater than -2 SDS and less than +2 SDS) | All participants who received at least one dose of study drug with at least one follow up visit. | Posted | Number | percentage of participants | Baseline through End of Study (up to 9 years) |
|
| |||||||||||||||||||||||||||||||||||||
| Secondary | Bone Age | Bone age measured using the X-Ray of left hand and wrist. | All participants who received at least one dose of study drug with at least one follow up visit. The safety follow up participants did not reach final height at end of Period 1 unless final height is noted for participants that reached final height at the end of Period 1. | Posted | Mean | Standard Deviation | years | Baseline through End of Study (up to 9 years) |
|
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Somatropin and Leuprorelin | Somatropin and leuprorelin n=46 | 12 | 46 | 41 | 46 | ||
| EG001 | Somatropin | Somatropin n=45 | 7 | 45 | 36 | 45 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Congenital genital malformation | Congenital, familial and genetic disorders | 18.0 | Systematic Assessment |
| |
| Thyroglossal cyst | Congenital, familial and genetic disorders | 18.0 | Systematic Assessment |
| |
| Complication of device removal | General disorders | 18.0 | Systematic Assessment |
| |
| Appendiceal abscess | Infections and infestations | 18.0 | Systematic Assessment |
| |
| Appendicitis | Infections and infestations | 18.0 | Systematic Assessment |
| |
| Gastroenteritis | Infections and infestations | 18.0 | Systematic Assessment |
| |
| Peritonitis | Infections and infestations | 18.0 | Systematic Assessment |
| |
| Viral infection | Infections and infestations | 18.0 | Systematic Assessment |
| |
| Fall | Injury, poisoning and procedural complications | 18.0 | Systematic Assessment |
| |
| Fracture | Injury, poisoning and procedural complications | 18.0 | Systematic Assessment |
| |
| Joint dislocation | Injury, poisoning and procedural complications | 18.0 | Systematic Assessment |
| |
| Radius fracture | Injury, poisoning and procedural complications | 18.0 | Systematic Assessment |
| |
| Road traffic accident | Injury, poisoning and procedural complications | 18.0 | Systematic Assessment |
| |
| Upper limb fracture | Injury, poisoning and procedural complications | 18.0 | Systematic Assessment |
| |
| Wrist fracture | Injury, poisoning and procedural complications | 18.0 | Systematic Assessment |
| |
| Histiocytosis | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 18.0 | Systematic Assessment |
| |
| Migraine | Nervous system disorders | 18.0 | Systematic Assessment |
| |
| Agitation | Psychiatric disorders | 18.0 | Systematic Assessment |
| |
| Intentional self-injury | Psychiatric disorders | 18.0 | Systematic Assessment |
| |
| Mental disorder | Psychiatric disorders | 18.0 | Systematic Assessment |
| |
| Suicidal ideation | Psychiatric disorders | 18.0 | Systematic Assessment |
| |
| Nephrolithiasis | Renal and urinary disorders | 18.0 | Systematic Assessment |
| |
| Renal colic | Renal and urinary disorders | 18.0 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Ear pain | Ear and labyrinth disorders | 18.0 | Systematic Assessment |
| |
| Hypothyroidism | Endocrine disorders | 18.0 | Systematic Assessment |
| |
| Abdominal pain | Gastrointestinal disorders | 18.0 | Systematic Assessment |
| |
| Abdominal pain upper | Gastrointestinal disorders | 18.0 | Systematic Assessment |
| |
| Diarrhoea | Gastrointestinal disorders | 18.0 | Systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | 18.0 | Systematic Assessment |
| |
| Toothache | Gastrointestinal disorders | 18.0 | Systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | 18.0 | Systematic Assessment |
| |
| Injection site pain | General disorders | 18.0 | Systematic Assessment |
| |
| Pyrexia | General disorders | 18.0 | Systematic Assessment |
| |
| Hypersensitivity | Immune system disorders | 18.0 | Systematic Assessment |
| |
| Bronchitis | Infections and infestations | 18.0 | Systematic Assessment |
| |
| Cystitis | Infections and infestations | 18.0 | Systematic Assessment |
| |
| Ear infection | Infections and infestations | 18.0 | Systematic Assessment |
| |
| Gastroenteritis | Infections and infestations | 18.0 | Systematic Assessment |
| |
| Influenza | Infections and infestations | 18.0 | Systematic Assessment |
| |
| Nasopharyngitis | Infections and infestations | 18.0 | Systematic Assessment |
| |
| Rhinitis | Infections and infestations | 18.0 | Systematic Assessment |
| |
| Tonsillitis | Infections and infestations | 18.0 | Systematic Assessment |
| |
| Tracheitis | Infections and infestations | 18.0 | Systematic Assessment |
| |
| Ligament sprain | Injury, poisoning and procedural complications | 18.0 | Systematic Assessment |
| |
| Vitamin d deficiency | Metabolism and nutrition disorders | 18.0 | Systematic Assessment |
| |
| Arthralgia | Musculoskeletal and connective tissue disorders | 18.0 | Systematic Assessment |
| |
| Pain in extremity | Musculoskeletal and connective tissue disorders | 18.0 | Systematic Assessment |
| |
| Scoliosis | Musculoskeletal and connective tissue disorders | 18.0 | Systematic Assessment |
| |
| Headache | Nervous system disorders | 18.0 | Systematic Assessment |
| |
| Cough | Respiratory, thoracic and mediastinal disorders | 18.0 | Systematic Assessment |
| |
| Epistaxis | Respiratory, thoracic and mediastinal disorders | 18.0 | Systematic Assessment |
| |
| Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | 18.0 | Systematic Assessment |
| |
| Acne | Skin and subcutaneous tissue disorders | 18.0 | Systematic Assessment |
|
No statistical analyses was performed after the early treatment termination. All data represented is descriptive statistics only and no confirmatory conclusions can be drawn from this study.
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Chief Medical Officer | Eli Lilly and Company | 800-545-5979 |
| ID | Term |
|---|---|
| D019382 | Human Growth Hormone |
| D013006 | Growth Hormone |
| D016729 | Leuprolide |
| ID | Term |
|---|---|
| D010908 | Pituitary Hormones, Anterior |
| D010907 | Pituitary Hormones |
| D036361 | Peptide Hormones |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
| D007987 | Gonadotropin-Releasing Hormone |
| D010906 | Pituitary Hormone-Releasing Hormones |
| D007028 | Hypothalamic Hormones |
| D009479 | Neuropeptides |
| D009842 | Oligopeptides |
| D009419 | Nerve Tissue Proteins |
| D011506 | Proteins |
Not provided
Not provided
| Male |
|
| Asian |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
| France |
|
|
|
|
| Participants |
|
|
| Units | Counts |
|---|---|
| Participants |
|
|
| Units | Counts |
|---|---|
| Participants |
|
|
| Units | Counts |
|---|
| Participants |
|
|
|
|